Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors (BEL)

This study has been completed.
Sponsor:
Collaborators:
Novartis
Genentech, Inc.
Information provided by (Responsible Party):
Herbert Hurwitz, Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT01055795
First received: January 24, 2010
Last updated: December 21, 2012
Last verified: December 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2012
  Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)